Critical Biologics Corporation Obtains $1,500,000 Series A Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d798afee-7d4f-4ac5-a36e-5c35ee1203f0&Preview=1 -
Date
8/22/2008 -
Company Name
Critical Biologics Corporation -
Mailing Address
124 Mt. Auburn St. Cambridge, MA 02138 -
Company Description
In particular, CBC is focused on a theranostic approach to treat critical care patients with low plasma gelsolin levels at high risk of life-threatening complications. -
Website
http://www.criticalbiologics.com -
Transaction Type
Venture Equity -
Transaction Amount
$1,500,000 -
Transaction Round
Series A -
Proceeds Purposes
The funds will enable CBC to advance its lead recombinant human plasma gelsolin (rhu-pGSN) targeted for the prevention of life-eatening critical care complications associated with low plasma gelsolin levels. -
M&A Terms
-
Venture Investor
Morningside Group
Share
